Telomir Pharmaceutical (TELO) has filed a proposed initial public offering of $14 million.
The biotech company set no conditions in its SEC filing, but indicated in a filing fee schedule that it was seeking to raise about $14 million. Kingswood Investments serves as main bookkeeper.
Telomir hopes to list its shares on Nasdaq under the symbol TELO.
Based in Maryland, Telomir’s lead drug candidate, TELOMIR-1, is an orally administered IL-17 inhibitor. The company plans to develop the drug, which is in the preclinical stage, as a potential treatment for post-chemotherapy recovery and age-related inflammatory diseases such as osteoarthritis.